| Literature DB >> 28821289 |
Ellen Winckelmans1, Tim S Nawrot2,3, Maria Tsamou1, Elly Den Hond4, Willy Baeyens5, Jos Kleinjans6, Wouter Lefebvre7, Nicolas Van Larebeke8, Martien Peusens1, Michelle Plusquin1, Hans Reynders9, Greet Schoeters7,10,11, Charlotte Vanpoucke12, Theo M de Kok6, Karen Vrijens1.
Abstract
BACKGROUND: Due to their lack of repair capacity mitochondria are critical targets for environmental toxicants. We studied genes and pathways reflecting mitochondrial responses to short- and medium-term PM10 exposure.Entities:
Keywords: Ambient air pollution; Particulate matter; Sex-specific, mitochondria; Transcriptome-wide analyses
Mesh:
Substances:
Year: 2017 PMID: 28821289 PMCID: PMC5563023 DOI: 10.1186/s12940-017-0292-7
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Descriptive characteristics for women and men of the discovery and validation cohort
| Characteristics | Discovery cohort (2004–2005) | Validation cohort (2012–2015) | ||
|---|---|---|---|---|
|
| Women ( | Men ( | Women ( | Men ( |
| Age, years | 57.8 [51.2–63.1] | 58.0 [51.5–64.0] | 58.1 [52.6–63.2] | 58.0 [52.5–63.6] |
| BMI, kg/m2 | 25.8 [22.1–31.1] | 27.4 [23.0–31.4] | 25.5 [20.4–32.8] | 26.1 [21.6–30.9] |
| WBC, cells/mcL | 6965 [5170–9360] | 6948 [5200–9270] | ||
| Socio-economic status | ||||
| Low | 28 (56.0) | 20 (41.7) | 23 (56.0) | 14 (18.7) |
| Medium | 7 (14.0) | 15 (31.3) | 16 (14.0) | 26 (34.7) |
| High | 15 (30.0) | 13 (27.1) | 55 (30.0) | 35 (46.7) |
| Smoking status | ||||
| Non-smokers | 50 (100.0) | 48 (100.0) | 80 (85.1) | 68 (90.7) |
| Smokers | - | - | 14 (14.9) | 7 (9.3) |
| Season of blood sampling | ||||
| Cold (October–March) | 40 (80.0) | 40 (83.3) | 40 (42.6) | 27 (36.0) |
| Warm (April–September) | 10 (20.0) | 8 (16.7) | 54 (57.4) | 48 (64.0) |
| Time of blood sampling | ||||
| < 12 pm | 44 (88.0) | 41 (85.4) | 7 (7.5) | 0 (0.0) |
| 12 pm–3 pm | 6 (12.0) | 7 (14.6) | 25 (26.6) | 20 (26.7) |
| 3 pm–6 pm | 0 (0.0) | 0 (0.0) | 43 (45.7) | 32 (42.7) |
| > 8 pm | 0 (0.0) | 0 (0.0) | 19 (20.2) | 23 (30.7) |
|
| ||||
| Short-terma PM10, μg/m3 | 29.3 [18.9–41.3] | 30.6 [20.4–41.4] | 19.6 [13.0–26.9] | 17.8 [12.6–24.0] |
| Short-terma PM2.5, μg/m3 | - | - | 12.8 [5.4–26.0] | 11.3 [5.8–17.7] |
| Medium-termb PM10, μg/m3 | 29.7 [24.2–40.5] | 31.5 [25.8–40.6] | 19.7 [13.8–26.7] | 17.5 [13.9–23.8] |
| Medium-termb PM2.5, μg/m3 | - | - | 12.7 [7.4–18.8] | 10.8 [7.6–16.9] |
| Long-termc PM10, μg/m3 | 26.0 [21.4–30.2] | 25.7 [21.4–30.1] | 24.2 [21.3–27.7] | 23.1 [20.8–25.8] |
| Long-termc PM2.5, μg/m3 | 17.8 [15.5–20.5] | 17.6 [15.6–20.3] | 16.0 [14.9–17.5] | 15.5 [14.6–16.5] |
| Week AT, °C | 5.8 [−1.3–11.9] | 3.4 [−1.5–11.6] | 15.4 [12.7–17.3] | 15.2 [12.7–17.3] |
| Month AT, °C | 7.1 [0.6–14.1] | 4.7 [0.6–11.2] | 15.3 [13.2–16.5] | 15.3 [13.2–17.2] |
aWeek before blood sampling
bMonth before blood sampling
cTwo-year averages
Data are number (%) or mean [10th-90th percentile]. AT apparent temperature
Top 10 most strongly associated Human MitoCarta genes with short-term PM10 exposure for women and men
| Gene symbol | Gene name | FC (95% CI) |
|
|
|---|---|---|---|---|
| Women | ||||
|
| polymerase (DNA) gamma, catalytic subunit | 0.83 (0.78, 0.90) | 1.31E-05 | 0.01 |
|
| mitochondrial ribosomal protein L38 | 0.83 (0.76, 0.90) | 1.08E-04 | 0.04 |
|
| mitochondrial ribosomal protein L16 | 0.83 (0.77, 0.91) | 1.46E-04 | 0.04 |
|
| 8-oxoguanine DNA glycosylase | 0.81 (0.73, 0.89) | 1.48E-04 | 0.04 |
|
| enoyl-CoA hydratase, short chain, 1, mitochondrial | 0.87 (0.81, 0.93) | 1.92E-04 | 0.04 |
|
| GTP binding protein 3 (mitochondrial) | 0.82 (0.74, 0.90) | 1.99E-04 | 0.04 |
|
| enoyl-CoA delta isomerase 2 | 0.84 (0.77, 0.92) | 2.86E-04 | 0.04 |
|
| ETHE1, persulfide dioxygenase | 0.86 (0.79, 0.92) | 3.23E-04 | 0.04 |
|
| polymerase (RNA) mitochondrial | 0.86 (0.80, 0.93) | 4.91E-04 | 0.06 |
|
| bolA family member 1 | 0.87 (0.81, 0.93) | 5.64E-04 | 0.06 |
| Men | ||||
|
| isopentenyl-diphosphate delta isomerase 1 | 1.20 (1.08, 1.33) | 1.31E-03 | 0.97 |
|
| creatine kinase, mitochondrial 1A | 1.30 (1.10, 1.53) | 4.09E-03 | 0.97 |
|
| phosphatidylglycerophosphate synthase 1 | 1.30 (1.10, 1.54) | 4.32E-03 | 0.97 |
|
| G protein subunit gamma 5 | 1.12 (1.04, 1.21) | 7.37E-03 | 0.97 |
|
| transmembrane BAX inhibitor motif containing 4 | 1.12 (1.03, 1.22) | 1.01E-02 | 0.97 |
|
| coiled-coil-helix-coiled-coil-helix domain containing 6 | 1.11 (1.03, 1.19) | 1.30E-02 | 0.97 |
|
| coiled-coil-helix-coiled-coil-helix domain containing 8 | 1.17 (1.04, 1.32) | 1.44E-02 | 0.97 |
|
| cytochrome c oxidase subunit 6A2 | 1.26 (1.06, 1.50) | 1.46E-02 | 0.97 |
|
| ribosomal protein L34 | 0.83 (0.72, 0.96) | 1.49E-02 | 0.97 |
|
| dehydrogenase/reductase 7B | 1.15 (1.03, 1.28) | 1.58E-02 | 0.97 |
FC fold change calculated for an increase in PM10 of 10 μg/m3
Top 10 most strongly associated Human MitoCarta genes with medium-term PM10 exposure for women and men
| Gene symbol | Gene name | FC (95% CI) |
|
|
|---|---|---|---|---|
| Women | ||||
|
| aldehyde dehydrogenase 7 family member A1 | 0.70 (0.54, 0.90) | 2.36E-04 | 0.21 |
|
| translocase of inner mitochondrial membrane 17 homolog B (yeast) | 1.05 (0.97, 1.13) | 3.90E-04 | 0.21 |
|
| glutamic-oxaloacetic transaminase 2 | 0.92 (0.68, 1.24) | 8.06E-04 | 0.23 |
|
| pyruvate dehyrogenase phosphatase catalytic subunit 2 | 1.04 (0.95, 1.15) | 9.34E-04 | 0.23 |
|
| glutaminase | 0.79 (0.62, 1.00) | 1.40E-03 | 0.23 |
|
| frataxin | 0.88 (0.81, 0.97) | 1.47E-03 | 0.23 |
|
| histidine triad nucleotide binding protein 2 | 0.97 (0.88, 1.06) | 2.46E-03 | 0.23 |
|
| ubiquinol-cytochrome c reductase hinge protein | 0.97 (0.86, 1.09) | 2.56E-03 | 0.23 |
|
| carnitine palmitoyltransferase 2 | 1.03 (0.94, 1.12) | 2.59E-03 | 0.23 |
|
| TruB pseudouridine synthase family member 2 | 0.98 (0.89, 1.07) | 3.25E-03 | 0.23 |
| Men | ||||
|
| mitochondrial ribosomal protein S15 | 1.23 (1.10, 1.38) | 1.14E-03 | 0.47 |
|
| ClpB homolog, mitochondrial AAA ATPase chaperonin | 1.36 (1.15, 1.61) | 1.15E-03 | 0.47 |
|
| solute carrier family 25 member 29 | 1.64 (1.24, 2.16) | 1.32E-03 | 0.47 |
|
| branched chain ketoacid dehydrogenase kinase | 1.24 (1.09, 1.43) | 3.37E-03 | 0.55 |
|
| stomatin-like 1 | 1.25 (1.08, 1.44) | 4.55E-03 | 0.55 |
|
| aarF domain containing kinase 1 | 1.33 (1.10, 1.61) | 5.22E-03 | 0.55 |
|
| solute carrier family 25 member 40 | 0.66 (0.50, 0.87) | 6.23E-03 | 0.55 |
|
| aldehyde dehydrogenase 7 family member A1 | 1.58 (1.16, 2.16) | 6.35E-03 | 0.55 |
|
| malate dehydrogenase 2 | 1.29 (1.09, 1.54) | 6.67E-03 | 0.55 |
|
| aldehyde dehydrogenase 1 family member B1 | 1.36 (1.10, 1.69) | 7.33E-03 | 0.55 |
FC fold change calculated for an increase in PM10 of 10 μg/m3
Top 15 significant pathways associated with short-term exposure
| Pathway | Effective/ total size | # ↓ genes | Contributing genes (#)§ |
|
|---|---|---|---|---|
| Women | ||||
| IL12-mediated signaling events | 57/67 | 33 |
| 1.8E-06 |
| role of mef2d in t-cell apoptosis | 28/31 | 25 |
| 1.2E-04 |
| T cell receptor signaling pathway | 96/104 | 52 |
| 8.0E-04 |
| Ribosome | 128/135 | 100 |
| 8.6E-04 |
| Natural killer cell mediated cytotoxicity | 104/134 | 50 |
| 1.0E-03 |
| Downstream signaling in naïve CD8+ T cells | 52/71 | 33 |
| 1.4E-03 |
| Formation of a pool of free 40S subunits | 94/151 | 71 |
| 1.5E-03 |
| Primary immunodeficiency | 32/36 | 24 |
| 2.0E-03 |
| TCR signaling in naïve CD8+ T cells | 54/58 | 35 |
| 2.0E-03 |
| Mitochondrial translation (elongation)* | 84/85 | 72 |
| 2.1E-03 |
| NF-κB signaling pathway | 86/91 | 43 |
| 2.8E-03 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 64/132 | 41 |
| 4.2E-03 |
| Busulfan Pathway, Pharmacodynamics | 30/36 | 16 |
| 4.5E-03 |
| Cell cycle | 116/124 | 63 |
| 4.6E-03 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 20/21 | 10 |
| 4.6E-03 |
| Men | ||||
| Meiotic recombination | 53/64 | 3 |
| 1.3E-12 |
| Cytokine Signaling in Immune system | 156/198 | 49 |
| 1.7E-04 |
| Osteoclast differentiation | 120/131 | 25 |
| 2.0E-04 |
| Phagosome | 135/155 | 35 |
| 3.7E-04 |
| GMCSF-mediated signaling events | 36/41 | 10 |
| 6.0E-04 |
| Legionellosis | 51/55 | 13 |
| 6.1E-04 |
| zTuberculosis | 151/179 | 46 |
| 6.9E-04 |
| Growth hormone receptor signaling | 17/20 | 1 |
| 6.9E-04 |
| Oncostatin_M | 37/40 | 9 |
| 7.5E-04 |
| IL3 Signaling Pathway | 47/40 | 13 |
| 1.2E-03 |
| Endogenous Toll-like receptor signaling | 25/27 | 5 |
| 1.2E-03 |
| Salmonella infection | 73/86 | 20 |
| 1.4E-03 |
| Kit receptor signaling pathway | 57/59 | 11 |
| 1.6E-03 |
| Toll-like receptor signaling pathway | 84/102 | 18 |
| 1.8E-03 |
| Cytoplasmic Ribosomal Proteins | 85/88 | 73 |
| 2.0E-03 |
# ↓ Number of down-regulated genes. §If more than 15 contributing genes only the top 5 is given. Mitochondrial pathways are marked with an asterisk and MitoCarta genes are indicated in bold type. IL: Interleukin; MEF2D: myocyte enhancer factor 2D; SMAD2,3,4: SMAD family member 2,3,4; GMCSF: Granulocyte-macrophage colony-stimulating factor
Top 15 significant pathways associated with medium-term exposure
| Pathway | Effective/ total size | # ↓ genes | Contributing genes (#)§ |
| |
|---|---|---|---|---|---|
| Women | |||||
| RNA Polymerase I Chain Elongation | 79/98 | 25 |
| 1.7E-04 | |
| Meiosis | 63/77 | 20 |
| 3.0E-04 | |
| RMTs methylate histone arginines | 64/74 | 23 |
| 3.8E-04 | |
| RNA Polymerase I Transcription | 100/121 | 35 |
| 5.7E-04 | |
| Mitochondrial translation (termination)* | 84/85 | 25 |
| 1.1E-03 | |
| phospholipids as signalling intermediaries | 30/36 | 12 |
| 1.9E-03 | |
| Meiotic recombination | 53/64 | 15 |
| 2.1E-03 | |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.* | 99/113 | 23 |
| 2.5E-03 | |
| Meiotic synapsis | 40/48 | 8 |
| 2.6E-03 | |
| Sirtuin 1 negatively regulates rRNA Expression | 59/76 | 18 |
| 2.7E-03 | |
| Condensation of Prophase Chromosomes | 64/77 | 17 |
| 2.8E-03 | |
| NoRC negatively regulates rRNA expression | 95/116 | 34 |
| 3.0E-03 | |
| RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | 133/159 | 48 |
| 3.2E-03 | |
| Platelet Aggregation (Plug Formation) | 28/38 | 9 |
| 3.7E-03 | |
| Respiratory electron transport* | 81/92 | 17 |
| 3.8E-03 | |
| Men | |||||
| 3-phosphoinositide biosynthesis | 25/29 | 10 |
| 2.0E-04 | |
| superpathway of inositol phosphate compounds | 62/71 | 31 |
| 2.8E-04 | |
| TCA cycle* | 27/34 | 7 |
| 3.7E-04 | |
| Citrate cycle (TCA cycle)* | 28/30 | 9 |
| 4.8E-04 | |
| PI Metabolism | 47/53 | 19 |
| 1.3E-03 | |
| IRS-related events triggered by IGF1R | 74/93 | 26 |
| 1.7E-03 | |
| Warburg Effect* | 43/45 | 15 |
| 2.5E-03 | |
| Synthesis of PIPs at the Golgi membrane | 15/20 | 6 |
| 2.7E-03 | |
| superpathway of conversion of glucose to acetyl CoA and entry into the TCA cycle | 44/52 | 13 |
| 2.9E-03 | |
| Histidine metabolism | 23/36 | 7 |
| 4.1E-03 | |
| Ghrelin | 31/44 | 7 |
| 4.7E-03 | |
| IL6 signaling pathway | 39/43 | 9 |
| 4.8E-03 | |
| Cell-Cell communication | 95/130 | 29 |
| 6.0E-03 | |
| Regulation of toll-like receptor signaling pathway | 116/142 | 38 |
| 6.6E-03 | |
| Downstream signaling of activated FGFR | 127/155 | 46 |
| 7.0E-03 | |
# ↓ Number of down-regulated genes. § If more than 15 contributing genes only the top 5 is given. Mitochondrial pathways are marked with an asterisk and MitoCarta genes are indicated in bold type. RMTs: arginine methyltransferases; IGF1R: insulin-like growth factor 1; FGFR: fibroblast growth factor receptors
Fig. 1Schematic overview of the mitochondrial respiratory electron transport chain and the genes significantly associated with medium-term PM10 exposure per complex in women. Green and red boxes indicate significantly up- and down-regulated genes respectively. Cyt c: cytochrome C
Fig. 2Schematic overview of the TCA cycle. Green boxes indicate significantly up-regulated genes and their corresponding protein in men in association to short-term PM10 exposure
Association between expression levels of the selected genes and PM exposure in women (n = 94) and men (n = 75) of the validation cohort
| Sex | Gene symbol | FC (95%CI) | P-val | FC (95%CI) | P-val | FC (95%CI) | P-val | FC (95%CI) | P-val | FC (95%CI) | P-val | FC (95%CI) | P-val |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Short-term PM10 | Short-term PM2.5 | Medium-term PM10 | Medium-term PM2.5 | Long-term PM10 | Long-term PM2.5 | ||||||||
| Women | Mt genome | ||||||||||||
|
| 0.76 (0.57,1.00) | 0.06 | 0.75 (0.57,1.00) | 0.05 | 0.65 (0.39,1.10) | 0.11 | 0.57 (0.32,1.01) | 0.06 | 0.90 (0.78,1.03) | 0.12 | 0.62 (0.45,0.86) | 0.005$$ | |
|
| 1.13 (0.92,1.37) | 0.25 | 1.11 (0.91,1.35) | 0.32 | 0.95 (0.68,1.34) | 0.78 | 0.95 (0.65,1.39) | 0.80 | 1.03 (0.94,1.13) | 0.57 | 1.21 (0.97,1.51) | 0.09 | |
|
| 0.92 (0.81,1.05) | 0.23 | 0.90 (0.79,1.03) | 0.13 | 0.79 (0.63,0.99) | 0.04 | 0.72 (0.56,0.93) | 0.01$ | 0.96 (0.90,1.02) | 0.22 | 0.88 (0.76,1.03) | 0.11 | |
|
| 0.84 (0.66,1.09) | 0.20 | 0.84 (0.65,1.08) | 0.19 | 0.64 (0.40,1.00) | 0.05 | 0.55 (0.34,0.90) | 0.02$ | 0.91 (0.80,1.03) | 0.15 | 0.70 (0.52,0.93) | 0.02$ | |
| ETC | |||||||||||||
|
| 1.22 (0.85,1.77) | 0.28 | 1.19 (0.83,1.72) | 0.35 | 1.50 (0.78,2.86) | 0.22 | 1.56 (0.76,3.22) | 0.23 | 1.19 (1.01,1.41) | 0.04 | 1.82 (1.23,2.70) | 0.004$$ | |
|
| 1.32 (0.90,1.93) | 0.16 | 1.29 (0.88,1.89) | 0.19 | 1.29 (0.66,2.49) | 0.46 | 1.42 (0.69,2.94) | 0.35 | 1.14 (0.96,1.37) | 0.15 | 1.81 (1.20,2.71) | 0.006$$ | |
|
| 1.15 (0.89,1.50) | 0.30 | 1.12 (0.87,1.46) | 0.38 | 1.01 (0.65,1.59) | 0.95 | 1.03 (0.63,1.69) | 0.90 | 1.05 (0.93,1.19) | 0.45 | 1.37 (1.03,1.81) | 0.03 | |
| Men | Mt genome | ||||||||||||
|
| 0.94 (0.86, 1.03) | 0.18 a | 0.95 (0.87, 1.04) | 0.33 a | 0.90 (0.77, 1.04) | 0.16 a | 0.90 (0.77, 1.05) | 0.17 a | 0.96 (0.92, 1.01) | 0.09 a | 0.91 (0.82, 1.01) | 0.07 a | |
|
| 0.96 (0.86, 1.08) | 0.52 | 0.98 (0.88, 1.1) | 0.78 | 0.88 (0.73, 1.06) | 0.17 | 0.88 (0.72, 1.07) | 0.19 | 1.01 (0.96, 1.06) | 0.76 | 0.99 (0.87, 1.12) | 0.88 | |
|
| 1.01 (0.92, 1.10) | 0.85 | 1.02 (0.94,1.11) | 0.61 | 1.08 (0.94, 1.24) | 0.29 | 1.08 (0.94, 1.26) | 0.29 | 1.03 (0.99, 1.07) | 0.22 | 1.05 (0.96, 1.16) | 0.27 | |
|
| 0.90 (0.81, 1.11) | 0.52 b | 0.98 (0.84, 1.14) | 0.82 b | 0.86 (0.67, 1.11) | 0.25 b | 0.89 (0.68, 1.15) | 0.37 b | 0.93 (0.87, 1.00) | 0.04 b | 0.80 (0.68, 0.94) | 0.01 b | |
| ETC | |||||||||||||
|
| 1.09 (0.85, 1.40) | 0.49 | 1.11 (0.88, 1.41) | 0.38 | 1.17 (0.78, 1.75) | 0.46 | 1.23 (0.81, 1.88) | 0.34 | 1.08 (0.96, 1.21) | 0.190 | 1.23 (0.94, 1.60) | 0.14 | |
|
| 1.14 (0.92, 1.41) | 0.25 | 1.16 (0.94, 1.44) | 0.16 | 1.39 (0.97, 1.98) | 0.07 | 1.41 (0.97, 2.04) | 0.07 | 1.12 (1.01, 1.24) | 0.04 | 1.32 (1.04, 1.69) | 0.03 | |
|
| 1.03 (0.93, 1.15) | 0.58 | 1.05 (0.95, 1.17) | 0.36 | 1.14 (0.96, 1.35) | 0.14 | 1.13 (0.95, 1.36) | 0.18 | 1.05 (1.00, 1.10) | 0.04 | 1.13 (1.01, 1.27) | 0.04 | |
FC Fold changes for an increase in PM of 10 μg/m3 (short- and medium-term) and 2 μg/m3 (long-term). Adjusted for age, BMI, smoking status, educational level, and time of blood sampling, temperature, WBC count, and percentage of neutrophils. Mt.: mitochondrial
a3 outliers with relatively low POLG expression removed
b1 outlier with relatively high LONP1 expression removed. Results including the outlier were similar (long-term PM2.5 p-val = 0.007). FDR-adjusted p-values <0.05$$ and <0.10$
Association between mtDNA content and PM exposure
| Time window | Men ( | Women ( | ||
|---|---|---|---|---|
| FC (95% CI) |
| FC (95% CI) |
| |
| Short-term PM10 | 0.80 (0.67, 0.96) | 0.02 | 0.82 (0.69, 0.97) | 0.02 |
| Short-term PM2.5 | 0.82 (0.69, 0.98) | 0.03 | 0.83 (0.7, 0.98) | 0.04 |
| Medium-term PM10 | 0.77 (0.57, 1.04) | 0.09 | 0.74 (0.55, 0.99) | 0.05 |
| Medium-term PM2.5 | 0.75 (0.55, 1.03) | 0.08 | 0.73 (0.53, 1.01) | 0.06 |
| Long-term PM10 | 0.95 (0.87, 1.04) | 0.26 | 0.9 (0.83, 0.97) | 0.007 |
| Long-term PM2.5 | 0.88 (0.72, 1.08) | 0.22 | 0.76 (0.64, 0.91) | 0.004 |
FC Fold changes for an increase in PM of 10 μg/m3 (short- and medium-term) and 2 μg/m3 (long-term). Adjusted for age, BMI, smoking status, educational level, and time of blood sampling, temperature and WBC count and percentage of neutrophils
Fig. 3Schematic representation of the hypothesised pathway by which PM exposure alters mitochondrial functioning and genome maintenance. Within the mitochondria, PM can interact with the electron transport chain inducing increased levels of ROS production. ROS can damage mtDNA leading to further mitochondrial dysfunctioning and ROS production. To repair or eliminate damaged cellular components, the electron transport genes are upregulated to provide the required energy. Elimination of damaged mtDNA and perturbation of mtDNA replication results in a reduction of mtDNA content. Eventually, accumulation of mitochondrial damage can lead to mitochondrial apoptotic signalling. TCA: Tri Carbonic Acid cycle; ETC: electron transport chain; mtDNA: mitochondrial DNA